TABLE 1.
Clinical and Pathologic Characteristics of 251 Patients
| Characteristic | No. of patients | Range | Percentage of patients |
| Median age at PET/CT (y) | 70 | 48–86 | |
| Further treatment | |||
| External radiation after radical prostatectomy | 110 | 43.8 | |
| Antihormonal treatment | 74 | 29.5 | |
| ADT within 6 mo before imaging | 60 | 23.9 | |
| Gleason score | |||
| ≤6 | 13 | 5.2 | |
| 7 | 125 | 49.8 | |
| ≥8 | 85 | 33.1 | |
| Unknown | 28 | 11.2 | |
| Pathologic primary tumor staging (pT) | |||
| pT2 | 74 | 29.5 | |
| pT3 | 92 | 36.7 | |
| pT4 | 7 | 2.8 | |
| Unknown | 78 | 31.1 | |
| Pathologic regional lymph node staging (pN) | |||
| pN0 | 123 | 49.0 | |
| pN1 | 41 | 16.3 | |
| pNx | 87 | 34.7 | |
| Positive margin | |||
| R0 | 80 | 31.8 | |
| R1 | 53 | 21.1 | |
| Unknown | 118 | 47.0 | |
| Median initial PSA level (ng/mL) | 10.9 | 0.6–250 | |
| Salvage radiation therapy before PET/CT | 110 | 43.8 | |
| Median time between surgery and PET/CT (mo) | 57 | 1–321 | |
| Median last PSA level before PET/CT (ng/mL) | 1.2 | 0.2–228 |